733600login-checkMedicare’s Bad Call on Transplant Tests |
Blood tests can save organs. Why are the feds denying coverage?
By The Editorial Board
Government spending on healthcare often leads to rationed care owing to rising costs. Think of the waiting lists in Canada and new price controls on U.S. drugs. Another mistake is playing out in care for organ-transplant patients denied coverage for blood tests that detect problems.
In March, MolDX, a program run by Medicare contractor Palmetto GBA to make coverage decisions on molecular lab tests, changed its guidance for when certain blood tests can be used. Read the full article in the Wall Street Journal.
733600login-checkMedicare’s Bad Call on Transplant Tests |